Literature DB >> 1822760

Heart rate variability and cardiac arrhythmias in patients with chronic renal failure.

B J Thomson1, D McAreavey, J M Neilson, R J Winney, D J Ewing.   

Abstract

Heart rate variability was measured from 24-h electrocardiograms in 61 patients with end stage chronic renal failure. The method used counts the number of times successive RR intervals differ by more than 50 ms over the 24-h period, and is a reliable indicator of cardiac parasympathetic activity. Also analysed were the frequency and type of ectopic beats and other arrhythmias. Twenty-one subjects (34%) had varying numbers of ventricular ectopic beats, and twelve (20%) had frequent supraventricular ectopics. Total 24-h count values were abnormal in 30 (76%) of the 41 subjects whose tapes were technically suitable for this analysis. There were no sex differences, but those patients maintained on haemodialysis had significantly lower counts than those on continuous ambulatory peritoneal dialysis. We conclude that about three-quarters of patients with chronic renal failure have abnormal cardiac parasympathetic activity. This may increase susceptibility to cardiac arrhythmias and sudden death and contribute to the high mortality of patients with chronic renal failure.

Entities:  

Mesh:

Year:  1991        PMID: 1822760     DOI: 10.1007/BF01826209

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  8 in total

1.  Twenty four hour heart rate variability: effects of posture, sleep, and time of day in healthy controls and comparison with bedside tests of autonomic function in diabetic patients.

Authors:  D J Ewing; J M Neilson; C M Shapiro; J A Stewart; W Reid
Journal:  Br Heart J       Date:  1991-05

2.  Cardiac parasympathetic activity during the early hours of acute myocardial infarction.

Authors:  D McAreavey; J M Neilson; D J Ewing; D C Russell
Journal:  Br Heart J       Date:  1989-09

3.  Decreased heart rate variability and its association with increased mortality after acute myocardial infarction.

Authors:  R E Kleiger; J P Miller; J T Bigger; A J Moss
Journal:  Am J Cardiol       Date:  1987-02-01       Impact factor: 2.778

Review 4.  Uraemic autonomic neuropathy.

Authors:  G Vita; C Messina; V Savica; G Bellinghieri
Journal:  J Auton Nerv Syst       Date:  1990-07

5.  New method for assessing cardiac parasympathetic activity using 24 hour electrocardiograms.

Authors:  D J Ewing; J M Neilson; P Travis
Journal:  Br Heart J       Date:  1984-10

6.  Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG).

Authors:  G Zuanetti; R Latini; J M Neilson; P J Schwartz; D J Ewing
Journal:  J Am Coll Cardiol       Date:  1991-03-01       Impact factor: 24.094

7.  Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemodialysed patients. Gruppo Emodialisi e Patologie Cardiovasculari.

Authors: 
Journal:  Lancet       Date:  1988-08-06       Impact factor: 79.321

8.  Chronic renal failure and cardiovascular autonomic function.

Authors:  S Malik; R J Winney; D J Ewing
Journal:  Nephron       Date:  1986       Impact factor: 2.847

  8 in total
  3 in total

1.  Heart rate and blood pressure variability in children with chronic kidney disease: a report from the CKiD study.

Authors:  Gina-Marie Barletta; Joseph Flynn; Mark Mitsnefes; Joshua Samuels; Lisa Aronson Friedman; Derek Ng; Christopher Cox; Timothy Poffenbarger; Bradley Warady; Susan Furth
Journal:  Pediatr Nephrol       Date:  2014-02-02       Impact factor: 3.714

Review 2.  Central and peripheral adaptations to physical training in patients with end-stage renal disease.

Authors:  E J Kouidi
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

Review 3.  Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease.

Authors:  Gino Seravalle; Fosca Quarti-Trevano; Jennifer Vanoli; Chiara Lovati; Guido Grassi
Journal:  Clin Auton Res       Date:  2021-02-19       Impact factor: 4.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.